MetaVia Inc. (NASDAQ:MTVA) Sees Large Increase in Short Interest

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totaling 344,566 shares, a growth of 177.8% from the June 30th total of 124,038 shares. Approximately 6.7% of the company’s shares are short sold. Based on an average daily volume of 1,041,508 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MTVA. Wall Street Zen upgraded MetaVia to a “sell” rating in a research report on Saturday, June 20th. HC Wainwright reissued a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.00.

Institutional Trading of MetaVia

A hedge fund recently bought a new position in MetaVia stock. Virtu Financial LLC purchased a new position in MetaVia Inc. (NASDAQ:MTVA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent quarter. 1.37% of the stock is currently owned by institutional investors.

MetaVia Trading Down 0.3%

NASDAQ:MTVA traded down $0.01 on Monday, reaching $1.48. 82,523 shares of the stock traded hands, compared to its average volume of 1,848,320. The company has a market capitalization of $7.61 million, a price-to-earnings ratio of -0.29 and a beta of 0.97. MetaVia has a 12 month low of $0.97 and a 12 month high of $19.03. The company’s fifty day simple moving average is $2.00 and its 200 day simple moving average is $2.08.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Equities analysts anticipate that MetaVia will post -2.78 EPS for the current fiscal year.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.